Hindustantimes wants to start sending you push notifications. Click allow to subscribe

Some hope amid Covid-19 gloom as US vaccine shows strong immune response in clinical trials

Washington [US] | ByAsian News International | Posted by Zarafshan Shiraz
Sep 26, 2020 02:18 PM IST

US vaccine supports safety profile and immunogenicity against Covid-19 after only a single dose

The US pharmaceutical and medical device company Johnson and Johnson has developed a vaccine that in the early trials showed a strong immune response to the novel coronavirus with a single dose, an interim report published on the medical website medRxiv revealed.

“The safety profile and immunogenicity after only a single dose are supportive for further clinical development of [vaccine] Ad26.COV2.S at a dose level of 5x1010 vp, as a potentially protective vaccine against COVID-19,” the report said on Friday. “A single dose of Ad26.COV2.S elicited strong humoral responses in the vast majority of vaccine recipients.”

Hindustan Times - your fastest source for breaking news! Read now.

The Johnson and Johnson vaccine is the fourth in the United States to enter the final phase of clinical trials.

President Donald Trump has promised that 100 million doses of a vaccine will be distributed throughout the United States by the end of the year. Trump said a vaccine could be available for distribution before the presidential election on November 3.

Many Democrats have accused Trump of trying to fast-track the vaccine approval process in order to get one delivered ahead of the November election.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Oscars 2024: From Nominees to Red Carpet Glam! Get Exclusive Coverage on HT. Click Here

Catch your daily dose of Fashion, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Start 14 Days Free Trial Subscribe Now
OPEN APP